These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27133763)

  • 1. Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma.
    Garel B; Kramkimel N; Trouvin AP; Frantz C; Dupin N
    Joint Bone Spine; 2017 Mar; 84(2):233-234. PubMed ID: 27133763
    [No Abstract]   [Full Text] [Related]  

  • 2. Crystal-induced oligoarthritis triggered by pembrolizumab, an immune checkpoint inhibitor.
    Corominas H; Badlissi F; Shmerling RH
    Joint Bone Spine; 2018 Oct; 85(5):647-648. PubMed ID: 29414722
    [No Abstract]   [Full Text] [Related]  

  • 3. Polymyalgia rheumatica occurring during treatment with ipilimumab.
    Maniu C; Kobe C; Schlaak M; Mauch C; Eming SA
    Eur J Dermatol; 2016 Oct; 26(5):513-514. PubMed ID: 27349150
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of arthritis under pembrolizumab.
    Salmon JH; Lambrecht I; Brochot P; Grange F
    Joint Bone Spine; 2017 Mar; 84(2):243-244. PubMed ID: 27118015
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymyalgia rheumatica due to pembrolizumab therapy.
    Iskandar A; Hwang A; Dasanu CA
    J Oncol Pharm Pract; 2019 Jul; 25(5):1282-1284. PubMed ID: 30249155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.
    Schmidgen MI; Butsch F; Schadmand-Fischer S; Steinbrink K; Grabbe S; Weidenthaler-Barth B; Loquai C
    J Dtsch Dermatol Ges; 2017 Jul; 15(7):742-745. PubMed ID: 28622432
    [No Abstract]   [Full Text] [Related]  

  • 7. Case report of polymyalgia rheumatica in a male patient with three different neoplasms treated with pembrolizumab.
    Perrotta FM; Scriffignano S; Fatica M; Specchia M; Lubrano E
    Reumatismo; 2020 Nov; 72(3):178-181. PubMed ID: 33213131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
    Amber KT; Valdebran M; Lu Y; De Feraudy S; Linden KG
    J Dtsch Dermatol Ges; 2018 Feb; 16(2):196-198. PubMed ID: 29389067
    [No Abstract]   [Full Text] [Related]  

  • 10. Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.
    Totonchy MB; Ezaldein HH; Ko CJ; Choi JN
    JAMA Dermatol; 2016 May; 152(5):590-2. PubMed ID: 26675815
    [No Abstract]   [Full Text] [Related]  

  • 11. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
    Chanal J; Kramkimel N; Ratour C; Aractingi S; Guégan S; Avril MF
    Dermatology; 2019; 235(3):219-224. PubMed ID: 30721908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
    Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
    Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyalgia rheumatica after pembrolizumab treatment.
    Ramirez-Poza S; Pardo-Cabello AJ; Salvatierra J
    Med Clin (Barc); 2023 Sep; 161(6):270-271. PubMed ID: 37271671
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    Maul LV; Weichenthal M; Kähler KC; Hauschild A
    J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
    JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract]   [Full Text] [Related]  

  • 16. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases.
    Navarrete-Dechent C; Cordova M; Postow MA; Pulitzer M; Lezcano C; Halpern AC; Rossi AM
    JAMA Dermatol; 2019 Mar; 155(3):347-352. PubMed ID: 30624578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superficial spreading melanoma.
    D'Ath P; Thomson P
    BMJ; 2012 Apr; 344():e2319. PubMed ID: 22496298
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
    N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment.
    Nakamagoe K; Moriyama T; Maruyama H; Yokosawa M; Hara T; Tanaka S; Fujimoto M; Tamaoka A
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1357-1358. PubMed ID: 28516380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.